Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Navigating the Biotech Landscape: Expert Insights from EvoLV Consultants

Oct 13, 2025

Understanding the Biotech Industry

The biotechnology sector is a rapidly evolving field, characterized by groundbreaking research and transformative innovations. As the industry expands, it is crucial for companies and investors to understand the complex landscape that defines this sector. EvoLV Consultants, a leader in biotech consulting, provides invaluable insights into navigating these complexities effectively.

Biotech companies are at the forefront of developing solutions that address some of the world's most pressing challenges, from healthcare to agriculture. The sector's dynamic nature requires a deep understanding of scientific advancements, regulatory environments, and market trends.

biotechnology lab

The Role of Regulatory Knowledge

One of the critical components of the biotech landscape is the regulatory framework that governs it. Successful navigation requires a comprehensive understanding of both domestic and international regulations. EvoLV Consultants emphasize that staying updated with these regulations is vital for ensuring compliance, minimizing risks, and accelerating product development timelines.

For many biotech firms, navigating the regulatory maze can be daunting. However, with expert guidance, companies can efficiently manage their regulatory strategies, thus enhancing their ability to bring innovative products to market swiftly.

Market Trends and Investment Opportunities

The biotech industry is not just about scientific breakthroughs; it also presents lucrative investment opportunities. Investors are increasingly drawn to this sector due to its potential for high returns. EvoLV Consultants highlight several key trends that are currently shaping the market:

  • The rise of personalized medicine and targeted therapies.
  • Increased focus on sustainable agricultural biotechnology.
  • Advancements in gene editing technologies.
  • Growing interest in biotech solutions for environmental challenges.
investment trends

By understanding these trends, investors can make informed decisions and identify promising ventures that align with their strategic goals.

Strategic Partnerships and Collaborations

In the biotech industry, strategic partnerships and collaborations are fundamental to driving innovation and growth. EvoLV Consultants stress the importance of forming alliances with academic institutions, research organizations, and other industry players. Such collaborations can lead to the sharing of knowledge, resources, and expertise, ultimately accelerating the development of innovative solutions.

Moreover, partnerships can open doors to new markets and customer segments, providing companies with a competitive edge in the global arena.

business collaboration

Embracing Technological Advancements

Technology is a key driver of change in the biotech sector. The integration of advanced technologies such as artificial intelligence, machine learning, and big data analytics is transforming how research is conducted and products are developed. EvoLV Consultants emphasize that embracing these technological advancements is essential for staying ahead in the competitive biotech landscape.

Companies that leverage technology effectively can enhance their research capabilities, optimize processes, and improve their overall operational efficiency, leading to accelerated innovation and growth.

Conclusion: The Path Forward

Navigating the biotech landscape requires a strategic approach that encompasses regulatory knowledge, market awareness, and technological integration. With expert insights from EvoLV Consultants, biotech companies and investors can position themselves for success in this rapidly evolving field. By staying informed and making strategic decisions, stakeholders can contribute to groundbreaking advancements that have the potential to transform industries and improve lives worldwide.